DATROWAY
Clinical safety rating: caution
Comprehensive clinical and safety monograph for DATROWAY (DATROWAY).
DATROWAY (datopotamab deruxtecan) is a trophoblast cell-surface antigen 2 (TROP-2)-directed antibody-drug conjugate (ADC). The antibody is a humanized monoclonal antibody conjugated to a topoisomerase I inhibitor payload (DXd) via a cleavable tetrapeptide linker. Binding to TROP-2 on tumor cells leads to internalization and intracellular release of DXd, which inhibits topoisomerase I, causing DNA damage and apoptosis.
| Metabolism | Metabolized by cathepsin B-mediated cleavage to release the DXd payload. DXd is primarily metabolized by CYP3A4. |
| Excretion | Primarily hepatobiliary excretion; unchanged drug and metabolites excreted in feces (~90%). Renal excretion is minor (<5%). |
| Half-life | Terminal elimination half-life is approximately 5-7 days. The long half-life supports a 3-week dosing interval. |
| Protein binding | >95% bound to plasma proteins, predominantly albumin. |
| Volume of Distribution | Vd is approximately 0.5-0.7 L/kg, indicating distribution mainly within vascular space and tissues. |
| Bioavailability | 100% intravenous only; not administered by any other route. |
| Onset of Action | Clinical effect (cytotoxic activity) begins within hours of intravenous administration as drug is rapidly internalized into tumor cells. |
| Duration of Action | Pharmacodynamic effects persist for the dosing interval (3 weeks) per clinical trial design. Systemic exposure remains above threshold for intrinsic activity throughout the 3-week cycle. |
6 mg/kg intravenously every 3 weeks until disease progression or unacceptable toxicity.
| Dosage form | INJECTABLE |
| Renal impairment | No formal renal adjustment recommended; eGFR ≥30 mL/min: no adjustment; eGFR <30 mL/min: insufficient data. |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B: reduce to 4.5 mg/kg; Child-Pugh C: not recommended due to lack of data. |
| Pediatric use | Safety and efficacy not established; no recommended dose in pediatric patients. |
| Geriatric use | No specific dose adjustment; monitor for increased toxicity given age-related comorbidities. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for DATROWAY (DATROWAY).
| Breastfeeding | No data on presence in human milk, effects on breastfed infant, or milk production. M/P ratio not available. Because of potential for serious adverse reactions in nursing infants, advise women not to breastfeed during treatment and for at least 4 months after last dose. |
| Teratogenic Risk | No adequate human data; based on animal studies, DATROWAY may cause fetal harm. First trimester: Risk of miscarriage and major malformations. Second and third trimesters: Risk of fetal growth restriction and oligohydramnios due to antibody-drug conjugate activity. Avoid in pregnancy unless benefit outweighs risk. |
■ FDA Black Box Warning
Interstitial lung disease (ILD) / pneumonitis: Fatal or life-threatening ILD/pneumonitis can occur. Monitor for signs/symptoms. Withhold or permanently discontinue based on severity.
| Serious Effects |
["None"]
| Precautions | ["Interstitial lung disease/pneumonitis","Neutropenia: severe, febrile neutropenia","Hypersensitivity reactions","Embryo-fetal toxicity: can cause fetal harm"] |
Loading safety data…
| Fetal Monitoring | Monitor for infusion reactions, hepatic function (AST, ALT, bilirubin), and ocular toxicity (dry eye, blurred vision). In pregnancy, perform serial ultrasounds to assess fetal growth and amniotic fluid volume. Monitor maternal blood pressure and urine protein for preeclampsia. |
| Fertility Effects | DATROWAY may impair male and female fertility based on animal studies. In females, it may induce ovarian failure (persistent amenorrhea, elevated FSH). In males, it may affect spermatogenesis. Preclinical studies show reduced fertility indices. |